Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.45 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.42 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.42 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15329139 | 1.00 | ALDH1A1 (0.54) | ALDH1A1GAACHRNA7CHRM2CHRM1 | |
| SCHEMBL2495325 | 0.98 | ALDH1A1 (0.51) | ALDH1A1GAACHRNA7CHRM2CHRM1 | |
| SCHEMBL5171234 | 0.98 | ALDH1A1 (0.51) | ALDH1A1GAACHRNA7CHRM2CHRM1 | |
| SCHEMBL1617171 | 0.98 | ALDH1A1 (0.51) | ALDH1A1GAACHRNA7CHRM2CHRM1 | |
| SCHEMBL9343685 | 0.95 | ALDH1A1 (0.50) | ALDH1A1GAACHRNA7CHRM2CHRM1 | |
| Acetic Acid SCHEMBL11614488 | 0.91 | ALDH1A1 (0.51) | ALDH1A1GAACHRNA7CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7499660 | 0.89 | ALDH1A1 (0.45) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 | |
| Hydrochloric Acid SCHEMBL2421080 | 0.89 | ALDH1A1 (0.45) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 | |
| Hydrochloric Acid SCHEMBL7498477 | 0.89 | ALDH1A1 (0.45) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 | |
| Hydrochloric Acid SCHEMBL7093326 | 0.89 | ALDH1A1 (0.45) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049727-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| EP-4429644-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ModernaTX, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023086465-A9 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| EP-4192433-A2 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | Modernatx, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023086465-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022032154-A2 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-103502213-B | Alkaloid ester and carbamate derivatives thereof and medicinal compositions | 奇斯药制品公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-2702041-A1 | ALKALOID ESTER AND CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | Chiesi Farmaceutici S.p.A. (IT) | 2014-03-05 | — | — | EP | disclosed |
| EP-0533241-A2 | Substituted alkyl derivatives of piperazinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0533240-A2 | Substituted amine derivatives of piperazinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0533242-A2 | Substituted derivatives of piperazinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0532097-A1 | Piperazinyl(sulfon)amide derivatives of camphor as oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0307141-B1 | OXAZOLES AND THIAZOLES FOR THE TREATMENT OF SENILE DEMENTIA | MERCK SHARP & DOHME LTD. (GB) | 1993-01-13 | — | — | EP | disclosed |
| US-5041456-A | Pharmaceutically useful 3-(indol-3-yl)-1,2,4-oxa- and thiadiazoles substituted in the 5-position by an amino containing group | MERCK SHARP & DOHME LTD. (GB) | 1991-08-20 | — | — | US | disclosed |
| US-4952587-A | PSYCHOLOGICAL DISORDERS, MIGRAINES, ALZHEIMER*S | MERCK SHARP & DOHME LTD. (GB) | 1990-08-28 | — | — | US | disclosed |
| EP-0328200-A1 | Five-membered ring systems with bonded azacyclic ring substituents | MERCK SHARP & DOHME LTD. (GB) | 1989-08-16 | — | — | EP | disclosed |
| EP-0307141-A2 | Oxazoles and thiazoles for the treatment of senile dementia | MERCK SHARP & DOHME LTD. (GB) | 1989-03-15 | — | — | EP | disclosed |
| US-4146628-A | NO SIDE EFFECTS | OPPENHEIMER EDNA | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049727-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | GAA 945/4885CHRNA7 3402/4885CHRM2 4595/4885 |
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | GAA 46/4885CHRNA7 1772/4885CHRM2 2959/4885 |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | GAA 945/4885CHRNA7 3402/4885CHRM2 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.